Vladimír Soška

Masaryk University, Brünn, South Moravian, Czech Republic

Are you Vladimír Soška?

Claim your profile

Publications (10)21.66 Total impact

  • V. Soška
    [Show abstract] [Hide abstract]
    ABSTRACT: Dyslipidemia is one of the main components of the metabolic syndrom. Is is characterized by elevated triglycerides, low HDL-cholesterol and elevated concentrations of small aterogenic LDL particles. The basic step in treatment should be always a lifestyle changes, especially changes in diet, weight optimization and ban of smoking. Pharmacotherapy DLP is indicated if a patient is in very high or high risk of fatal cardiovascular event during next 10 years and if (at the same time) is LDL-cholesterol higher than its target level. Pharmacotherapy is based on statins therapy, in case of their intolerance ezetimibe. If target level of LDL-cholesterol is achieved and persist elevated levels of triglycerides and/or decreased HDL-cholesterol, adding fenofibrate to a statin should be considered.
    No preview · Article · Jan 2015 · Interni Medicina pro Praxi
  • [Show abstract] [Hide abstract]
    ABSTRACT: This position statement of the Executive Committee of the Czech Society for Atherosclerosis (CSAT) summarizes the most important aspects and novelties of the latest European guidelines for the management of dyslipidemia. In particular the position statement comments on: cardiovascular risk stratification, indications for plasma lipid and lipoprotein levels assessment as well as target lipid values, evaluation of current options for both lifestyle and pharmacological treatment of lipid metabolism disorders and, also, recommendation for laboratory monitoring of patients treated with lipid lowering agents. The statement deals with actual concepts of management of dyslipiemia in everyday practice, e.g. therapy of dyslipidemia in special patients´ groups. This statement does not replace the latest guidelines but focuses on the changes from the former guidelines for dyslipidemia management, published by CSAT in 2007.Key words: dyslipidemia - risk stratification - LDL-cholesterol - statins - fibrates - niacin - ezetimibe - resins.
    No preview · Article · Feb 2013 · Vnitr̆ní lékar̆ství

  • No preview · Article · Jan 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Familial hypercholesterolemia (FH), a major risk for coronary heart disease, is predominantly associated with mutations in the genes encoding the low-density lipoprotein receptor (LDLR) and its ligand apolipoprotein B (APOB). In this study, we characterize the spectrum of mutations causing FH in 2239 Czech probands suspected to have FH. In this set, we found 265 patients (11.8%) with the APOB mutation p.(Arg3527Gln) and 535 patients (23.9%) with a LDLR mutation. In 535 probands carrying the LDLR mutation, 127 unique allelic variants were detected: 70.1% of these variants were DNA substitutions, 16.5% small DNA rearrangements, and 13.4% large DNA rearrangements. Fifty five variants were novel, not described in other FH populations. For lipid profile analyses, FH probands were divided into groups [patients with the LDLR mutation (LDLR+), with the APOB mutation (APOB+), and without a detected mutation (LDLR-/APOB-)], and each group into subgroups according to gender. The statistical analysis of lipid profiles was performed in 1722 probands adjusted for age in which biochemical data were obtained without FH treatment (480 LDLR+ patients, 222 APOB+ patients, and 1020 LDLR-/APOB- patients). Significant gradients in i) total cholesterol (LDLR+ patients > APOB+ patients = LDLR-/APOB- patients) ii) LDL cholesterol (LDLR+ patients > APOB+ patients = LDLR-/APOB- patients in men and LDLR+patients > APOB+ patients >LDLR-/APOB- patients in women), iii) triglycerides (LDLR-/APOB- patients > LDLR+ patients > APOB+ patients), and iv) HDL cholesterol (APOB+ patients > LDLR-/APOB- patients = LDLR+ patients) were shown. Our study presents a large set of Czech patients with FH diagnosis in which DNA diagnostics was performed and which allowed statistical analysis of clinical and biochemical data.
    No preview · Article · May 2012 · Atherosclerosis
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to determine whether the atherogenic index of plasma (AIP=log[triglycerides/HDL-cholesterol]) differs in heterozygous familial hypercholesterolemia (FH) patients with and without a history of cardiovascular disease (CVD). A total of 555 FH patients with known mutations in the LDL receptor or the apolipoprotein B gene, of whom 53 had a history of CVD (CVD+ group), were retrospectively analyzed. Compared to patients without CVD (CVD- group), CVD+ patients showed significantly higher fasting LDL-cholesterol, triglycerides and AIP as well as lower HDL-cholesterol. After both adjustment for age and diabetes and using analysis based on age and sex matched groups, only the increase in triglycerides and AIP in the CVD+ vs. the CVD- group remained significant. The results of the present study indicate that AIP, which reflects the presence of atherogenic small LDL and small HDL particles, may be connected to the risk of CVD in FH patients.
    Full-text · Article · Nov 2011 · Clinical biochemistry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Familial hypercholesterolemia (FH) is an inborn disorder of lipid metabolism characterised by elevated plasma concentrations of low-density lipoprotein cholesterol and total cholesterol. This imbalance results in accelerated atherosclerosis and premature coronary heart disease. The early identification and treatment of FH patients is extremely important because it leads to significant reduction of both coronary morbidity and mortality. FH is transmitted in an autosomal dominant manner and associated predominantly with mutations in the genes encoding the low-density lipoprotein receptor (LDLR) and its ligand apolipoprotein B (APOB). To date, more than 1000 sequence variants have been described in the LDLR gene. In marked contrast to LDLR, only one APOB mutation is prevalent in Europe. The aim of this study was, on the basis of data obtained by the molecular genetic analysis of 1945 Czech FH probands, to propose, generate, and validate a new diagnostic tool, an APEX (Arrayed Primer EXtension)-based genotyping DNA microarray called the FH chip. The FH chip contains the APOB mutation p.Arg3527Gln, all 89 LDLR point mutations and small DNA rearrangements detected in Czech FH patients, and 78 mutations frequent in other European and Asian FH populations. The validation phase revealed the sensitivity and specificity of this platform, 100% and 99.1%, respectively. This FH chip is a rapid, reproducible, specific, and cost-effective tool for genotyping, and in combination with MLPA (multiple ligation-dependent probe amplification) represents a reliable molecular genetic protocol for the large-scale screening of FH mutations in the Czech population.
    Preview · Article · May 2011 · Atherosclerosis
  • Věra Zelená · Robert Kuba · Vladimír Soška · Ivan Rektor
    [Show abstract] [Hide abstract]
    ABSTRACT: The etiology of sexual dysfunction in patients with epilepsy is perceived as multifactorial, with seizure and medication effects being the most often discussed and analyzed factors. We used common statistical methods to evaluate the impact of type of epilepsy, antiepileptic medication, hormones, seizure control, and symptoms of depression and anxiety on sexual function in a group of 78 women with epilepsy. To assess sexual function, we used the Female Sexual Function Index (FSFI). To assess symptoms of depression and anxiety, we used the Beck Depression and Anxiety Inventories (BDI, BAI). Of all the observed factors, only BDI score was significantly correlated with FSFI score. There was no correlation between FSFI, hormonal levels, seizure frequency, and symptoms of anxiety. No differences were found between patients with focal and those with generalized epilepsies; between seizure-free and non-seizure-free patients; or in relation to the number and type of antiepileptic medications.
    No preview · Article · Feb 2011 · Epilepsy & Behavior
  • [Show abstract] [Hide abstract]
    ABSTRACT: The following recommendation is further to the recommendations for diagnosis and treatment of hyperlipoproteinemia in childhood issued by the Czech Society for Atherosclerosis in 1998 and reflects the change in the development of occurrence of dyslipidemia and other risk factors of ischemic heart disease in the pediatric population, such as obesity, hypertension, diabetes mellitus, insulin resistance and smoking. It is also further to the amended recommendations of the American Heart Association, which were recently published this year. They represent a contribution to the practical strategy for the prevention of atherosclerosis during childhood, which is applied mainly by general practitioners for children and adolescents and by pediatric cardiologists. One of the main tasks of pediatricians is to have a preventive influence on the entire pediatric population, and in particular to achieve early detection of children with a high risk of early atherosclerosis, especially those with familial hypercholesterolemia and familial apolipoprotein B-100 deficiency and to treat them adequately. The recommendation takes into account the latest knowledge in the area of pathophysiology of dyslipidemia and experience with new therapeutic procedures in children. The recommendation also includes a table (attached) with a practical instruction for how to proceed in daily practice, what values should be achieved in children and which means should be selected.
    No preview · Article · Jan 2008

  • No preview · Article · Jul 2000 · Atherosclerosis
  • Source

    Full-text · Article · Jan 1998 · Human Mutation

Publication Stats

45 Citations
21.66 Total Impact Points


  • 2011-2012
    • Masaryk University
      • Department of Biochemistry
      Brünn, South Moravian, Czech Republic
    • St. Ann's University Hospital Brno
      Brünn, South Moravian, Czech Republic
    • St. Anne´s University Hospital
      Brünn, South Moravian, Czech Republic
  • 1998
    • University Hospital Brno
      • Department of Clinical Biochemistry
      Brno, South Moravian Region, Czech Republic